^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

ORIC-533

i
Other names: ORIC-533
Associations
Trials
Company:
ORIC Pharma
Drug class:
CD73 inhibitor
Associations
Trials
4ms
ORIC-533-01: Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=56, Active, not recruiting, ORIC Pharmaceuticals | Recruiting --> Active, not recruiting | Phase classification: P1b --> P1 | Trial completion date: Jun 2024 --> Sep 2024 | Trial primary completion date: Jun 2024 --> Sep 2024
Enrollment closed • Phase classification • Trial completion date • Trial primary completion date
|
ORIC-533
7ms
Journal
|
CD73 (5'-Nucleotidase Ecto)
|
ORIC-533
2years
CD73 Inhibition Reverses Immunosuppression and Has Potential As an Immunomodulatory Therapy in Patients with Multiple Myeloma (ASH 2022)
This study, together with our previous reports, confirms that CD73 inhibition can reduce adenosine generation, overcome immune suppression, and restore lysis of MM cells. Based on these results, ORIC-533 is being studied as a single agent in a Phase 1 clinical trial in patients with relapsed or refractory multiple myeloma.
Clinical • IO biomarker
|
NT5E (5'-Nucleotidase Ecto) • SDC1 (Syndecan 1)
|
CD73 overexpression • CD73 expression • NT5E overexpression
|
ORIC-533
over2years
ORIC-533, a small molecule CD73 inhibitor with best-in-class properties, reversesimmunosuppression and has potential as an immunomodulatory therapy in patients with multiple myeloma (AACR 2022)
Recent clinical proof of concept data demonstrated a significant improvement in progression free survival for non-small cell lung cancer patients upon targeting CD73 with the oleclumab anti-CD73 antibody in combination with anti-PDL1, relative to anti-PDL1 checkpoint inhibitor treatment alone.We developed ORIC-533, a potent, orally bioavailable, AMP-competitive, small molecule inhibitor of CD73, that is highly selective for CD73 and exhibits picomolar potency in biochemical assays, completely blocking adenosine production from AMP. Taken together, these results demonstrate that the ORIC CD73 inhibitor potently inhibits the adenosine pathway, which restores anti-tumor immunity and therefore holds potential for patients with MM. Based upon these data, ORIC-533 is being studied as a single agent in a Phase 1 clinical trial in patients with relapsed or refractory multiple myeloma.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8)
|
CD73 overexpression • CD73 expression • NT5E overexpression
|
oleclumab (MEDI9447) • ORIC-533
3years
CD73 Inhibition Overcomes Immunosuppression and Triggers Autologous T-Cell Mediated Multiple Myeloma Cell Lysis in the Bone Marrow Milieu (ASH 2021)
This study therefore demonstrates that: 1. CD73-mediated adenosine activity suppresses the cytolytic activity of T-cells against tumor cells in the MM BM milieu; and 2. CD73 inhibition can overcome immune suppression and restore lysis of MM cells by autologous T-cells.
IO biomarker
|
CD8 (cluster of differentiation 8) • CD73 (5'-Nucleotidase Ecto) • CD69 (CD69 Molecule) • NT5E (5'-Nucleotidase Ecto) • CD40 (CD40 Molecule) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1) • CD86 (CD86 Molecule)
|
CD73 overexpression • CD73 expression • NT5E overexpression
|
ORIC-533
over3years
[VIRTUAL] Blocking adenosine production with ORIC-533, a CD73 inhibitor with best-in-class properties, reverses immunosuppression in high-AMP environments (AACR 2021)
Taken together, these preclinical results indicate the CD73 inhibitor ORIC-533 has best-in-class properties in reversing immunosuppression in tumors. ORIC-533 is currently undergoing GLP studies to support an IND filing in the first half of 2021.
Late-breaking abstract
|
CD8 (cluster of differentiation 8) • CD73 (5'-Nucleotidase Ecto) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • NT5E (5'-Nucleotidase Ecto)
|
CD73 overexpression • IL2RA expression • CD73 expression • NT5E overexpression
|
ORIC-533